From: Cynthia Janak [mailto:email@example.com]
Sent: Friday, August 21, 2009 9:21 AM
To: 'Leslie Botha'
Subject: H1N1 to the scientists.
To the Esteemed members of the Robert Koch Institute and Health Minister of Germany,
The Advocates of the International Coalition of Advocates for the People once again request your attention to a matter of urgency.
As you know there is a plan to vaccinate every man, woman and child, regardless of previous medical conditions, pregnancy or other health concerns. This is very worrisome to the coalition. The attached documents have been compiled by the members of the International Coalition of Advocates for the People in regards to the safety and efficacy of the novel H1N1 vaccines that are going to be administered to the citizens in the very near future.
The coalition after intense research and investigations into the patents and ingredients of these novel vaccines believe that there is a serious health and safety issue. The impact of the potential harm that could be caused, first to the children and pregnant women, requires your immediate attention to the data that the coalition is presenting to you today.
As you will see in the data provided that several of the ingredients have the potential to affect the central nervous system, are known neurotoxins that can be transferred via the placenta to the unborn fetus and can cause infertility.
We understand that you are very concerned about the health and wellness of all citizens of the European Union. The members of the International Coalition of Advocates for the People share your concerns for your citizens and understand that the sustainability of providing adequate health care is paramount.
Hence, our urgency in presenting this new found information to the Institute and to the Health Minister.
Thank you for your patience and your continued efforts on behalf of the health and wellness of the citizens of the world.
Founder & President
Treatise on the A/H1N1 flu vaccines from the United States
Authors: Cynthia Janak, Research Journalist, President of an International Coalition and Dr. True Ott, PhD. ND. Naturopath, Investigative Clinician.
Since March, 2009, the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), through the news media, have created the impression that a “novel” strain of H1N1 (swine) flu virus has appeared and that it will mutate and spread pandemically all across the world. Deemed “unstoppable,” the only way to protect the world’s nearly 7 billion people, according to WHO et al, is to “develop” a vaccine, produce nearly five billion doses of it and vaccinate the entire planet—children and pregnant women first.
The evidence, however, shows that the “novel” H1N1 “virus” strain is a product of scientific research and the patented vaccine has been under development for at least four years. The implication of this research undermines the WHO/CDC/media-created impression that a global cooperative of public health officials and vaccine manufacturers are responding appropriately to a pending public health emergency.
In our research we have found that there are unusual and serious dangers posed to citizens from the vaccines coming out of a pandemic which is based on an engineered virus. The ensuing global vaccine campaign is made up of vaccines stemming from this engineered virus. Our treatise is an educational tool full of information. Our areas of main concern are regarding the following important topics.
In March, 2009, a new strain of influenza was detected in the country of Mexico and was deemed a “novel” or new and unique virus. Since that time, there have been several admissions reported in the mainstream media that provide foundational clues as to our concern that the H1N1 influenza vaccine was patented to be sold as the antidote for an H1N1 influenza strain created in labs.
CNN reported April 24, 2009 that CDC Influenza Division Director Nancy Cox, PhD, said, “The new virus has genes from North American swine and avian influenza, human influenza, and swine influenza normally found in Asia and Europe.” (1) The next day (April 25, 2009) CNN reported that WHO Epidemic and Pandemic Disease spokesman Gregory Hartl said, “The strain of the virus seen in Mexico is worrisome because it has mutated from older strains.” (2) On May 22, 2009, the World Health Organization’s “Weekly Epidemiological Record” noted that, “Most cases [of swine flu] appear to have uncomplicated, typical influenza-like illness and [afflicted individuals] recover spontaneously.” (3) This appears to be patently true, as the CDC admits that reported death rates per thousands of infections are much lower with this “novel virus” than death rates commonly ascribed to “seasonal” influenza.
On June 11, 2009, the WHO Regional Office for Europe announced, “Today WHO raised the level of influenza A(H1N1) pandemic alert to phase 6, as sustained community-level transmission of the virus is taking place in more than one region of the world. The term pandemic means that an influenza virus that is new to human beings has appeared, is spreading and is causing disease in many parts of the world. Globally, it is of moderate severity.” (4) Regardless that the epidemiological data, May, 2009, Novartis received a $289 million order from the US Department of Health and Human Services for A(H1N1) vaccine with proprietary adjuvant MF59© (5)
This paper will focus on eight areas: (1) Novartis patent information regarding flu vaccine composition. (2) Individual ingredients involved in the creation of this vaccine. Reports documenting adverse events in regards to ingredients of this vaccine. (3) Genetically modified vaccines and foods and their dangers. (4) Vaccine challenge and re-challenge in regards to multiple vaccinations. (5) Aluminum and thimerosal content of vaccines. (6) Other pandemic influenza vaccines approved by the European Medicines Agency. (7) Mandatory vaccination hazards. (8) Preventative measures.
Novartis patent information – Pub. No.: US 2009/0047353 A1, Pub. Date: Feb. 19, 2009 -
1.2Split virions – (Disclosure of the Invention)
1.2.10007…the clinical and epidemiological features of ORS are suggestive of hypersensitivity, and so it has been proposed that the vaccine may upset the natural Th1/Th2 balance,
1.2.20008 …the invention seeks to minimize the possibility that a split vaccine might cause an excessive Th2 response. In a situation where influenza vaccines have to be produced in a hurry (e.g. after a pandemic outbreak) then pressures on manufacturers might inadvertently result in the release of vaccines that suffer from the same problems as the partially un-split aggregated Canadian batches from 2000-01.
1.3The Split Influenza Virus Antigen
1.3.10032 – The influenza virus may be a reassortant strain, and may have been obtained by reverse genetics techniques.
22.214.171.124Reverse genetics techniques [e.g. 16 – 20] allow influenza viruses with desired genome segments to be prepared in vitro using plasmids.
126.96.36.199… they involve expressing (a) DNA molecules that encode desired viral RNA molecules
188.8.131.52(b) DNA molecules that encode viral proteins
184.108.40.206… it is also possible to use a helper virus to provide some of the RNA and proteins.
1.3.20036 – may include one or more RNA segments
220.127.116.11from a A/PR/8/34 virus (typically 6 segments from A/PR/8/34, with HA and N segments being from a vaccine strains, i.e. a 6:2 reassortant).
18.104.22.168from a A/WSN/33 virus,
22.214.171.124or from any other virus strain useful for generating reassortant viruses for vaccine preparation
1.3.30037 – viruses used as the source of the antigens are grown on cell culture.
126.96.36.199.1origin include, but are not limited to, hamster, cattle, primate (including humans and monkeys) and dog cells.
188.8.131.52.2Cell types may be used, such as kidney cells, fibroblasts, retinal cells, lung cells, etc.
184.108.40.206.3Hamster cells – BHK21 or HKCC
220.127.116.11.4Monkey cells – African green monkey – kidney cells – Vero cell line.
18.104.22.168.5Dog cells – kidney cells – MDCK cell line.
22.214.171.124.6Thus suitable cell lines include, but are not limited to: MDCK; CHO; 293T; BHK; Vero; MRC-5; PER C6; WI-38; etc.